MentionFoxFairfield Bio, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-10-06.
Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Fairfield Bio, Inc.
Free to see. No signup.
We'll show it in your MentionFox inbox when Fairfield Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Fairfield Bio, Inc. →Get the full cited report on Fairfield Bio, Inc.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Fairfield Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 4199 filings in Other, totalled by week. The dot is this raise, $1.95M, on the same scale — one filing against the whole group's total, so it sits low by construction.
This is an estimate of the gross proceeds of the offering that will be paid out to officers and managers over the following 12 months if no other monies are earned by the company.
Kevin Slavin is named as Executive Officer and Director on the Form D that Fairfield Bio, Inc. filed with the SEC on 6 October 2026, one of 2 people that filing names.
Mitchell Wolfe is named as Executive Officer and Director on the Form D that Fairfield Bio, Inc. filed with the SEC on 6 October 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-10-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Fairfield Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fairfield Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Fairfield Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Fairfield Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Fairfield Bio, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/fairfield-bio-inc-form-d-000002